Jennifer E Gerber1, Janesse Brewer1, Rupali J Limaye1,2,3,4,5, Andrea Sutherland1, Madeleine Blunt1, Taylor A Holroyd1,4, Gail Geller3,6,7,8, Bruce Carleton9,10,11, Jeffery Kahn6, Daniel A Salmon1,3,5. 1. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3. Department of Health Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 4. International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 5. Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 6. Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA. 7. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 8. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. 9. Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, BC, Canada. 10. Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 11. British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.
Abstract
Objective: We characterize public values regarding vaccinomics, which aims to improve vaccine safety and effectiveness using genomics. Methods: Panel survey (2020) of ≥18-year-olds with embedded animation introduced vaccinomics. Sociodemographic, health, and vaccination-related items were adapted from validated scales. Novel items measured trust in public health authorities, vaccinomics-related values, and preferences for federal funding: vaccinomics compared with vaccine issues and chronic diseases. Beginning and end of survey confidence in vaccine safety was measured to assess potential changes. Data were weighted to the U.S. Census. Vaccinomics-related concerns were stratified by sociodemographic characteristics, vaccine hesitancy status (composite outcome), reported serious vaccine reactions, and trust in public health authorities (PHA). Log binomial regression models estimated associations between these variables and agency to make vaccine-related decisions. Results: Most (70.7%, N = 1,925) respondents expected vaccinomics would increase their vaccine confidence compared to now. Agreement was highest among those without serious vaccine reaction experience (unexperienced: 74.2% versus experienced: 62.3%), with high trust in PHA (high: 83.3% versus low: 57.4%), and low vaccine hesitancy among parents of teenagers (low: 78.8% versus high: 62.5%) and adults without minor children (low: 79.8% versus high: 60.6%; all p < .01). Belief that vaccination was an individual's choice was associated with reported serious reactions (adjusted Prevalence Ratio (aPR): 1.16; 95% CI: 1.07, 1.25) and low trust (aPR: 0.91; 0.84, 0.98). Beginning versus end of survey vaccine safety perceptions were similar. Conclusion: Federal funding, communications, and policies should assure the public that vaccinomics will not remove their decision-making power and engender trust in PHA.
Objective: We characterize public values regarding vaccinomics, which aims to improve vaccine safety and effectiveness using genomics. Methods: Panel survey (2020) of ≥18-year-olds with embedded animation introduced vaccinomics. Sociodemographic, health, and vaccination-related items were adapted from validated scales. Novel items measured trust in public health authorities, vaccinomics-related values, and preferences for federal funding: vaccinomics compared with vaccine issues and chronic diseases. Beginning and end of survey confidence in vaccine safety was measured to assess potential changes. Data were weighted to the U.S. Census. Vaccinomics-related concerns were stratified by sociodemographic characteristics, vaccine hesitancy status (composite outcome), reported serious vaccine reactions, and trust in public health authorities (PHA). Log binomial regression models estimated associations between these variables and agency to make vaccine-related decisions. Results: Most (70.7%, N = 1,925) respondents expected vaccinomics would increase their vaccine confidence compared to now. Agreement was highest among those without serious vaccine reaction experience (unexperienced: 74.2% versus experienced: 62.3%), with high trust in PHA (high: 83.3% versus low: 57.4%), and low vaccine hesitancy among parents of teenagers (low: 78.8% versus high: 62.5%) and adults without minor children (low: 79.8% versus high: 60.6%; all p < .01). Belief that vaccination was an individual's choice was associated with reported serious reactions (adjusted Prevalence Ratio (aPR): 1.16; 95% CI: 1.07, 1.25) and low trust (aPR: 0.91; 0.84, 0.98). Beginning versus end of survey vaccine safety perceptions were similar. Conclusion: Federal funding, communications, and policies should assure the public that vaccinomics will not remove their decision-making power and engender trust in PHA.
Authors: Neal A Halsey; Mari Griffioen; Stephen C Dreskin; Cornelia L Dekker; Robert Wood; Devindra Sharma; James F Jones; Philip S LaRussa; Jenny Garner; Melvin Berger; Tina Proveaux; Claudia Vellozzi; Karen Broder; Rosanna Setse; Barbara Pahud; David Hrncir; Howard Choi; Robert Sparks; Sarah Elizabeth Williams; Renata J Engler; Jane Gidudu; Roger Baxter; Nicola Klein; Kathryn Edwards; Maria Cano; John M Kelso Journal: Vaccine Date: 2013-10-08 Impact factor: 3.641
Authors: Sara Y Tartof; Hung Fu Tseng; Amy L Liu; Lei Qian; Lina S Sy; Rulin C Hechter; S Michael Marcy; Steven J Jacobsen Journal: Vaccine Date: 2014-03-25 Impact factor: 3.641
Authors: Omolade Oladejo; Kristen Allen; Avnika Amin; Paula M Frew; Robert A Bednarczyk; Saad B Omer Journal: Vaccine Date: 2016-08-23 Impact factor: 3.641
Authors: Manisha Patel; Adria D Lee; Nakia S Clemmons; Susan B Redd; Sarah Poser; Debra Blog; Jane R Zucker; Jessica Leung; Ruth Link-Gelles; Huong Pham; Robert J Arciuolo; Elizabeth Rausch-Phung; Bettina Bankamp; Paul A Rota; Cindy M Weinbaum; Paul A Gastañaduy Journal: MMWR Morb Mortal Wkly Rep Date: 2019-10-11 Impact factor: 17.586